At $117.03, CoreWeave (NASDAQ:CRWV) looks fully valued near current levels, with a more attractive risk/reward setup on any macro-induced pullback to $105 or below. The stock has ripped 18.87% in the past week as traders front-run Nasdaq-100 inclusion on June 22, 2026, making this an awkward spot to chase but a dangerous one to short.
CoreWeave operates a purpose-built AI cloud platform renting GPU compute to model developers, hyperscalers, and enterprise customers. The company surpassed 1 GW of active power in Q1 and positioned itself as the preferred infrastructure layer for inference workloads, with CEO Michael Intrator saying CoreWeave sits “between the models and the silicon.”.
The stock IPO’d at $40 in March 2025, ran to $187, and now trades near its 50-day moving average of $108.98 as the market digests a backlog explosion alongside escalating losses.
The Bull Case: Backlog Math
CoreWeave booked $99.4 billion of revenue backlog, including a $21 billion Meta commitment and $6 billion from Jane Street. Management signed more than $40 billion of new commitments in Q1 alone and now counts ten customers committed to spending at least $1 billion. Guidance for 2026 sits at $12 billion to $13 billion in revenue with an exit run rate of $18 billion to $19 billion, and management flagged a 2027 run rate above $30 billion, of which more than 75% is already contracted. NVIDIA’s $2 billion equity investment validates the moat. Cantor Fitzgerald carries a $167 target, and the June 22 Nasdaq-100 inclusion mechanically forces passive funds to buy.
The Bear Case: Debt Load
Total liabilities hit $50.81 billion, quarterly interest expense doubled to $536 million, and Q2 interest expense is guided to $650 million to $730 million. Q1 free cash flow was negative $4.71 billion on $7.7 billion of CapEx, with full-year 2026 CapEx guided to $31 billion to $35 billion.
Net loss widened to $740 million from $315 million a year earlier, and EPS of -$1.40 missed consensus by 16.26%. Insiders unloaded over $100 million in May and June, with CEO Intrator selling up to $37.65 million in shares. A securities fraud class action alleging concealed data center construction delays still hangs over the name.
Valuation at $117
At 8.81x trailing sales and 11.53x book, the stock prices in flawless backlog conversion. The Nasdaq-100 catalyst is real, yet much appears in the 18.87% one-week rally. Buying after that move and ahead of inclusion day risks a classic “sell the news” reversal.
A pullback toward the 200-day moving average of $100.09 or the $105 buy zone would offer cleaner risk/reward into Q2 results. Leaked bond memoranda reportedly show 90% of 2027 ARR is already secured, which would validate the bull math, but the stock needs to digest its move first.
Analyst Consensus
Shares trade at $117.03 against a consensus analyst target of $140.18, implying 19.78% upside. Of the 35 analysts covering the stock:
- Strong Buy: 3
- Buy: 19
- Hold: 11
- Sell: 1
- Strong Sell: 1
CRWV is up 63.43% year to date against the broader S&P 500, yet still sits 26.16% below where it traded a year ago. Q1 revenue of $2.08 billion grew 111.69% year over year and beat consensus by 5.80%.
Where Things Stand at $117
The Nasdaq-100 inclusion bid is largely priced in after a near 19% weekly surge. Chasing a known-date catalyst punishes latecomers when passive funds finish rebalancing. The fundamental setup is constructive, with a $99.4 billion backlog and 2027 run rate guidance above $30 billion, but entry matters when the company burns $4.71 billion of free cash flow per quarter.
A constructive re-rating signal would be a macro-driven pullback to the $105 zone, aligning with the 200-day moving average and improving risk/reward. A bearish signal would be a Q2 print showing margin recovery stalling or interest expense outrunning the $650 to $730 million guide, either calling the backlog conversion thesis into question.
Watch contracted power conversion, adjusted operating margin (guided to low double digits by Q4), and customer diversification beyond hyperscalers. At $105, the same backlog would be available roughly 10% cheaper with a defined invalidation level, offering a cleaner setup for risk-conscious entries.
Top Gaining Stocks
Top Losing Stocks